

Applicants : Ron S. Israeli et al.
Serial No. : 08/470,735
Filed : June 6, 1995
Page 2

In the claims:

Please cancel claims ~~97~~, and ~~102-104~~ without prejudice to applicants' rights to pursue the subject matter in a future application.

Please amend claim 93 under 27 C.F.R. §1.121(b) by inserting the underlined material.

① --93. (Amended) An antibody which binds to a polypeptide having the biological activity of a prostate specific membrane antigen with the proviso that the antibody is not the 7E11-C5 monoclonal antibody.--

REMARKS

Claims 93-104 are pending in the subject application. By this amendment, applicants have amended claim 93. Claim 93 is amended such that it will not cover the known monoclonal antibody designated 7E11-C5. Accordingly, there are no issues of new matter and applicants respectfully request the entry of this Amendment.

The Examiner rejected claim 93 under 35 U.S.C. 102(b) as being anticipated by Feng, et al. (1991). The Examiner stated that Feng, et al. discloses of a isolated PSM antigen with a molecular weight of 110 kda and an antibody which reacts with said antigen.

In response but without conceding the correctness of Examiner's position and to expedite the prosecution of the subject matter, applicants have hereinabove amended claim 93. Applicants believe that the amended claim 93 should obviate this ground of rejection.